Global Plaque Psoriasis Market – Industry Trends and Forecast to 2029

Plaque Psoriasis Market Analysis and Insights

Plaque psoriasis is the most basic form of psoriasis, accounting for 80 to 90 percent of total psoriasis cases. Plaque psoriasis is an autoimmune condition characterized by thick, red patches on the skin. These plaques are most commonly found on the knees, scalp, and elbows. However, these can also appear on other parts of the body. These are itchy, painful, and have the potential to bleed. The precise cause of plaque psoriasis is unknown.

The plaque psoriasis is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the plaque psoriasis market will grow at a CAGR of 6.50% during the forecast period of 2022 to 2029. The market value, which was USD 26.37 billion in 2021 will reach USD 47.24 billion in 2029. The growing demand for better healthcare infrastructure is driving the plaque psoriasis market forward.

Market Definition

Plaque psoriasis is the most basic form of psoriasis and accounts for 80% to 90% cases of total psoriasis. Plaque psoriasis is an autoimmune condition, in which thick, red patches appear on the skin. These plaques generally appear on the knees, scalp, and elbows. however, these can also appear on other body part. These are itchy, painful, and can bleed. The exact cause of plaque psoriasis is still unknown.

Plaque Psoriasis Market scope and segmentation

Plaque psoriasis Market Dynamics

Drivers

• Rise in psoriasis prevalence

The rise in psoriasis prevalence and a rich promising pipeline of drugs are expected to drive growth in the plaque psoriasis market during the forecast period.

• Increasing investment for healthcare infrastructure

The change in lifestyle is expected to fuel the growth of the plaque psoriasis market. Furthermore, an increase in treatment awareness is expected to cushion the growth of the plaque psoriasis market

• High prevalence of alcohol and smoking consumption

Increased alcohol and smoking consumption, an unhealthy diet, and sedentary living will fuel the growth of the plaque psoriasis market in the coming years.

growth rate plaque psoriasis market in future.

Restraints/Challenges

The negative side effects of existing medications, on the other hand, are expected to stymie the growth of the plaque psoriasis market over the forecast period. Furthermore, however, because there is no disease-modifying treatment available for the conditions, and current treatment only provides symptomatic relief, the growth of the plaque psoriasis market may be hampered in the near future.

This plaque psoriasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on plaque psoriasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Plaque psoriasis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Plaque Psoriasis Market

The COVID-19 pandemic initially had a negative growth impact on the psoriasis market, owing to guidelines published by various regulatory bodies indicating that patients receiving psoriasis treatment are more likely to become infected with COVID-19. The International Psoriasis Council (IPC) recommended that physicians discontinue or postpone the prescription of immunosuppressant medications in March 2020. However, in September 2020, researchers from the University of Pennsylvania's Perelman School of Medicine and 16 other research institutions from the United States and Canada, in collaboration with the National Psoriasis Foundation, developed guidelines to care for psoriasis patients during the coronavirus pandemic. The researchers discovered no evidence that medical interventions for psoriasis and psoriatic arthritis should be discontinued or altered in order to reduce COVID-19 risks.

Recent Development

• POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis, yielded positive results in November 2020 for Bristol Myers Squibb.
• After receiving marketing authorization from the European Commission in May 2020 for indications including psoriatic arthritis and plaque psoriasis, Lupin Limited and Mylan launched the biosimilar etanercept Nepexto in Germany in August 2020.
• Fujifilm Kyowa Kirin Biologics received Japanese regulatory approval in July 2020 for the manufacturing and marketing of the first adalimumab biosimilar in the island country for the indications of psoriasis vulgaris, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, entero-disease, Behcet's Crohn's disease, and polyarticular-course juvenile

Global Plaque Psoriasis Market Scope

The plaque psoriasis market is segmented on the basis of treatment, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Topical therapy
• Phototherapy
• Systemic agents
• Biologic therapies
• Others

Route of Administration

• Oral
• Injectable

End Use

• Hospitals
• Homecare
• Speciality centres
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Pipeline Analysis

Taltz (Ixekizumab), Cosentyx (Secukinumab), Siliq (Brodalumab), Tremfya (Guselkumab), Ilumya (Tildrakizumab), and SKYRIZI are examples of major approved Interlunkin antibodies (Risankizumab).

Plaque Psoriasis Market Regional Analysis/Insights

The plaque psoriasis market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, indications, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the plaque psoriasis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the plaque psoriasis market due to the increased prevalence of the disease. Moreover, the plaque psoriasis market in the region will benefit from a robust drug pipeline during the forecast period. Because of the increase in research expenditure, Asia-Pacific is expected to see significant growth in the plaque psoriasis market. Furthermore, rising public awareness of the disease is expected to drive the growth of the plaque psoriasis market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Plaque Psoriasis Market Share Analysis

The plaque psoriasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to plaque psoriasis market.

Some of the major players operating in the plaque psoriasis market are

• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Bayer AG (Germany)
• Merck & Co., Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (US)
• Cadila Pharmaceuticals (India)
• Eli Lilly and Company (US)
• LEO Pharma A/S (Denmark)
• Cipla Inc. (US)
• Aurobindo Pharma (India)
• Lupin (India)
• Sumitomo Corporation (Japan)

SKU-46052